



HEALTH INFORMATION *designs*



**West Virginia
Department of Health and Human
Resources**

**Bureau for Medical Services
Drug Utilization Review Board**

May 31, 2017

First Quarter 2017

○ Profiles Reviewed	1,719	
○ Cases Identified		1,411
○ Letters Mailed		
○ Prescribers	1,688	
○ Pharmacies	1,735	
○ Responses		
○ Prescribers	199	11.7%
○ Pharmacies	248	14.3%



First Quarter 2017

January RDUR Criteria:

- **Controlled substances**
- **Multiple criteria for antidepressant under utilization**
 - **Amitriptyline, doxepin, nortriptyline, protriptyline, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, mirtazapine, venlafaxine, duloxetine, desvenlafaxine, vilazodone, levomilnacipran, vortioxetine**



First Quarter 2017

February RDUR Criteria:

- **Controlled substances**
- **Under-utilization**
 - **Trazodone**
 - **Bupropion**
 - **Lovaza**
- **Non-adherence to lipid lowering agents**



First Quarter 2017

February Educational Intervention:

- **Therapeutic appropriateness of benzodiazepines**
 - **Long-term use of benzodiazepines**
 - **Duplicate benzodiazepine and sedative/hypnotics**
 - **Duplicate benzodiazepines**
 - **Concurrent omeprazole and diazepam or clorazepate**
 - **Cases Reviewed: 781**
 - **Letters Sent: 1,488**



First Quarter 2017

March RDUR Criteria:

- **Controlled substances**
- **Co-administration**
 - **Oxycodone and CYP3A4 inhibitors**
 - **Oxycodone and CYP3A4 inducers**
 - **Opioids and skeletal muscle relaxants**
 - **SSRIs and triptans**
- **Therapeutic duplication**
 - **Antiulcer agents**
 - **Anxiolytics**
 - **Benzodiazepines**



First Quarter 2017

Proposed Educational Interventions

- **Opioid MME restriction for new members**
 - December mailed 1,297 MD letters for 4,735 affected members in current population
- **Identify new members on non-formulary test strips**
 - MD letters informing affected patients
- **FDA's Drug Safety Communications**
 - Codeine and tramadol use in children



First Quarter 2017

Distribution of Cases:

- **Drug-Disease Interactions: 3%**
 - Patients receiving a drug that may worsen or precipitate a medical condition.
- **Drug-Drug Conflict: 37%**
 - Patients receiving two or more drugs that may interact and produce unpredictable and undesirable effects.
- **Over-utilization: 10%**
 - Patients taking medications in apparently excessive doses or for excessive lengths of time.
- **Non-compliance: 19%**
 - Patients not taking medication according to directions, resulting in possible sub-therapeutic response.
- **Clinical Appropriateness: 31%**
 - Patients who are taking medications for treatment of a disease for which the medication is not standard of care.



First Quarter 2017

Evaluation

- **Extremely useful 20**
- **Useful 41**
- **Somewhat useful 2**
- **Neutral 14**
- **Not useful 6**



Fourth Quarter 2017

Lock-In

• Profiles Reviewed	162
• Total Cases	114
• Case Rate	70.4%
• Warning Cases	86
• Lock-In (LI) Cases	10
• Cases Continued in LI	12
• Cases Removed from LI	2



Questions?

